Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.55 |
| ▸ | FADS1 | O60427 | 2/20 | 0.54 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794596 | 0.82 | GRM4 (1.00) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7346388 | 0.78 | TRPA1 (0.69) | GRM4CYP3A4TRPA1FADS1ADRA2A | |
| SCHEMBL19794745 | 0.76 | GRM4 (0.73) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19794631 | 0.74 | GRM4 (0.76) | GRM4CYP1A2CYP2C9TRPA1FADS1 | |
| SCHEMBL19801468 | 0.74 | GRM4 (0.76) | GRM4CYP1A2CYP2C9FADS1 | |
| SCHEMBL17194815 | 0.74 | IMPDH2 (0.65) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4741513 | 0.73 | TRPA1 (0.75) | GRM4CYP3A4TRPA1FADS1ADRA2A | |
| SCHEMBL29882003 | 0.73 | TRPA1 (0.75) | GRM4CYP3A4TRPA1FADS1ADRA2A | |
| SCHEMBL19794602 | 0.72 | GRM4 (0.69) | GRM4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL802142 | 0.71 | GRM4 (0.66) | GRM4TRPA1FADS1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227343-B2 | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | GRIA4, GRM4, GRIK4 | GRM4 2/4885CYP1A2 1511/4885CYP3A4 480/4885 |
| US-20180022745-A1 | ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | GRIA4, GRM4, GRIK4 | GRM4 2/4885CYP1A2 1511/4885CYP3A4 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.